个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG.

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Shu-Nan Qi[1] * ; Yong Yang[1] * ; Yu-Qin Song[2] * ; Ying Wang[3] ; Xia He[4] ; Chen Hu[5] ; Li-Ling Zhang[6] ; Gang Wu[6] ; Bao-Lin Qu[7] ; Li-Ting Qian[8] ; Xiao-Rong Hou[9] ; Fu-Quan Zhang[9] ; Xue-Ying Qiao[10] ; Hua Wang[11] ; Gao-Feng Li[12] ; Hui-Qiang Huang[13] ; Yu-Jing Zhang[13] ; Yuan Zhu[14] ; Jian-Zhong Cao[15] ; Jun-Xin Wu[16] ; Tao Wu[17] ; Su-Yu Zhu[18] ; Mei Shi[19] ; Li-Ming Xu[20] ; Zhi-Yong Yuan[20] ; Hang Su[21] ; Jun Zhu[2] ; Ye-Xiong Li[1] ;
机构： [1]National Cancer Center/Cancer Hospital, Center for Cancer Precision Medicine, Chinese Academy of Medical Sciences–Peking Union Medical College, National Institute of Biological Sciences, Collaborative Innovation Center for Cancer Medicine, Beijing, People’s Republic of China [2]Key Laboratory of Carcinogenesis and Translational Research,Ministry of Education, Peking University Cancer Hospital & Institute, Beijing, People’s Republic of China [3]Chongqing University Cancer Hospital–Chongqing Cancer Hospital, Chongqing, People’s Republic of China [4]Jiangsu Cancer Hospital–Jiangsu Institute ofCancerResearch,Nanjing,People’s Republic of China [5]Division of Biostatistics and Bioinformatics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD [6]Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China [7]The General Hospital of Chinese People’s Liberation Army, Beijing, People’s Republic of China [8]The Affiliated Provincial Hospital of Anhui Medical University, Hefei, People’s Republic of China [9]Peking Union Medical College Hospital, Chinese Academy of Medical Sciences–Peking Union Medical College, Beijing, People’s Republic of China [10]The Fourth Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China [11]Second Affiliated Hospital of Nanchang University, Nanchang, People’s Republic of China [12]Beijing Hospital, National Geriatric Medical Center, Beijing, People’s Republic of China [13]Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine,Guangzhou, People’s Republic of China [14]Zhejiang Cancer Hospital, Hangzhou, People’s Republic of China [15]Shanxi Cancer Hospital and the Affiliated Cancer Hospital of Shanxi Medical University, Taiyuan, People’s Republic of China [16]Fujian Provincial Cancer Hospital, Fuzhou, People’s Republic of China [17]Affiliated Hospital of Guizhou Medical University, Guizhou Cancer Hospital, Guiyang, People’s Republic of China [18]Hunan Cancer Hospital–Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, People’s Republic of China [19]Xijing Hospital of Fourth Military Medical University, Xi’an, People’s Republic of China [20]Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention–Therapy, National Clinical Research Center for Cancer, Tianjin, People’s Republic of China [21]The Fifth Medical Center of PLA General Hospital, Beijing, People’s Republic of China
出处：
DOI： 10.1182/bloodadvances.2020001852
ISSN：

关键词： Non–ANT-based regimen chemotherapy was associated with a survival improvement in the entire cohort and risk subgroups

摘要：
The present study investigated the survival benefit of non-anthracycline (ANT)-based vs ANT-based regimens in a large-scale, real-world cohort of patients with extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKTCL). Within the China Lymphoma Collaborative Group (CLCG) database (2000-2015), we identified 2560 newly diagnosed patients who received chemotherapy with or without radiotherapy. Propensity score matching (PSM) and multivariable analyses were used to compare overall survival (OS) and progression-free survival (PFS) between the 2 chemotherapy regimens. We explored the survival benefit of non-ANT-based regimens in patients with different treatments in early-stage disease and in risk-stratified subgroups. Non-ANT-based regimens significantly improved survivals compared with ANT-based regimens. The 5-year OS and PFS were 68.9% and 59.5% for non-ANT-based regimens compared with 57.5% and 44.5% for ANT-based regimens in the entire cohort. The clinical advantage of non-ANT-based regimens was substantial across the subgroups examined, regardless of stage and risk-stratified subgroup, and remained significant in early-stage patients who received radiotherapy. The survival benefits of non-ANT-based regimens were consistent after adjustment using multivariable and PSM analyses. These findings provide additional evidence supporting non-ANT-based regimens as a first-line treatment of patients with ENKTCL. © 2020 by The American Society of Hematology.

基金：
Chinese Academy of Medical Science Innovation Fund for Medical Sciences (CIFMS;2016-I2M-1-001), the National Key Projects of Research and Development of China (2016YFC0904600), Capital’s Funds for Health Improvement and Research (grant 2018-1-2151),and the National Natural Science Foundation of China (grants 81670185 and 81870154).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院分区：
出版当年[2020]版：
大类 | 2 区 医学
小类 | 2 区 血液学
最新[2025]版：
大类 | 1 区 医学
小类 | 2 区 血液学
JCR分区：
出版当年[2020]版：
Q1 HEMATOLOGY
最新[2023]版：
Q1 HEMATOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者：
第一作者机构： [1]National Cancer Center/Cancer Hospital, Center for Cancer Precision Medicine, Chinese Academy of Medical Sciences–Peking Union Medical College, National Institute of Biological Sciences, Collaborative Innovation Center for Cancer Medicine, Beijing, People’s Republic of China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Shu-Nan Qi,Yong Yang,Yu-Qin Song,et al.First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG.[J].BLOOD ADVANCES.2020,4(13):3141-3153.doi:10.1182/bloodadvances.2020001852.
APA：
Shu-Nan Qi,Yong Yang,Yu-Qin Song,Ying Wang,Xia He...&Ye-Xiong Li.(2020).First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG..BLOOD ADVANCES,4,(13)
MLA：
Shu-Nan Qi,et al."First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG.".BLOOD ADVANCES 4..13(2020):3141-3153

相关文献

[1]VEP-M在视觉通路病变中的应用价值(附18例报道) [2]智能化舌体(形)测算仪的研制及应用-附1733例患者检测初步分析 [3]阿帕替尼治疗腹腔低度恶性肌纤维母细胞肉瘤1例及文献回顾 [4]肺结节中西医结合全程管理专家共识 [5]早发型胃癌的特点及研究进展 [6]micrornas在口腔扁平苔藓组织中的表达谱分析及3种mirna的血清学表达 [7]基于cesm影像与病理指标预测乳腺癌her-2和ki-67表达的价值 [8]grhl2与雌激素相关性肿瘤发展关系的研究进展 [9]pd-l1与肿瘤相关免疫细胞的表达在口腔鳞状细胞癌发生发展中的作用 [10]CRISPR/Cas9基因编辑技术在肿瘤研究及治疗中的应用

资源点击量：39770 今日访问量：0 总访问量：1333 更新日期：2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持：重庆聚合科技有限公司 地址：河北省石家庄市健康路12号